Leveraging Our Groundbreaking Technology to Treat Pain and Diseases of the Nervous System
Why Pancreatic Cancer and Pancreatitis-Related Pain Are Compelling Opportunities
Significant Unmet Need
Pancreatic cancer-related pain is a daunting issue, primarily due to its location near critical nerves and vessels, leading to severe, resistant pain. Traditional pain treatments, including opioids, frequently prove inadequate, leaving countless patients in desperate need of more effective solutions.
Speed to Market
Pancreatic cancer and pancreatitis-related pain, though smaller markets, offers distinct development benefits that can accelerate our market entry, especially in terms of clinical trials. Smaller patient population often translates to shorter enrollment times and decreasing trial durations. Achieving “proof-of-concept” in this area opens the door to blockbuster diseases, expanding the horizons for our technology.
Cost of Development
Developing a treatment for a large blockbuster mark is expensive. By initially targeting pancreatic cancer and pancreatitis-related pain, smaller markets, we are able to leverage a number of cost-efficient advantages, particularly around clinical trial development. The smaller and shorter clinical trials potentially translate to more efficient resource utilization, minimizing overall development costs.
Current Approaches to Pain Are Lacking and Patients Are Suffering
Pancreatic cancer and pancreatitis-related pain can be complex and challenging to manage. Current approaches, primarily relying on opioids and palliative care, can provide only limited relief and may lead to tolerance and side effects. As a result, there is a pressing need for more effective and targeted solutions to improve the quality of life for patients.
Opioid Pain Medications
Can lead to side effects like sedation, constipation, and the development of tolerance over time, requiring higher and higher doses. Potential to lead to addiction.
Nerve Blocks
Nerve blocks can be effective for neuropathic pain, but they may provide only temporary relief, requiring repeat procedures. Additionally, not all patients are candidates for nerve blocks.
Nerve Ablation
Techniques come with challenges related to precision and targeting. It is currently challenging to precisely pinpoint the affected nerves without affecting nearby structures. This lack of precision can lead to unintended side effects and incomplete pain relief.
With our catheter-based sensing technology, we’re developing the ability to do two things at once: sense neural signals that indicate pain or disease and destroy those nerves at the source. We believe this is a better alternative to the current approaches commonly used today. The Autonomix technology uses our proprietary microchip and unique antenna sensing array to deliver precise treatments through a simple and safe transvascular procedure.
We are developing what we believe to be a better alternative to the current approaches commonly used today, where doctors treat suspected areas in an attempt to hit the right nerves. This approach is often inaccurate and can miss the target and even cause collateral damage to surrounding nerves.
We believe our technology can potentially treat a large number of diseases related to the dysregulation of the nervous system, including chronic pain, cardiovascular disease and pulmonary disease. Our initial focus is on helping pancreatic cancer patients and people with pancreatitis suffering from severe pain not adequately managed with existing methods. We believe this approach provides us the best opportunity to demonstrate “proof of concept” while being the quickest to market.
Autonomix’s technology holds the potential to usher in a new era of personalized medicine by allowing doctors to tailor treatments to individual neural profiles. This precision can lead to more effective interventions, fewer side effects and improved patient experiences across a spectrum of diseases.
The transvascular approach is groundbreaking because it enables doctors to access nearly any nerve within the body through familiar catheters. This approach opens new avenues for minimally invasive diagnosis and targeted treatment of conditions involving the peripheral nervous system, offering patients safer and more effective solutions.
Autonomix achieves high sensitivity by using the patented microchip small enough to place immediately adjacent to the antenna detecting the signals, which greatly reduces the distance the signals must travel.
This approach provides a safer and more effective alternative by targeting the specific nerves responsible for pain or disease. This minimizes the reliance on painkillers and opioids, which often come with side effects and diminishing effectiveness over time. The goal is to improve patient outcomes and quality of life by offering precise and lasting relief.
Autonomix Medical, Inc.
21 Waterway Ave, Suite 300
The Woodlands, TX 77380
LEGAL DISCLAIMER
This presentation (the “presentation”) has been prepared for use by Autonomix Medical, Inc. (“Autonomix”) in connection with their proposed offering. This presentation is for information purposes only and is being provided to assist interested parties in making their own evaluation with respect to a potential investment, and for no other purpose. This presentation may not be reproduced or redistributed, in whole or in part, without the prior written consent of Autonomix. Autonomix does not make any representation or warranty as to the accuracy or completeness of the information contained in this presentation. This presentation is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in connection with the proposed offering and is not intended to form the basis of any investment decision. You should consult your own legal, regulatory, tax, business, financial and accounting advisors to the extent you deem necessary and must make your own investment decision and perform your own independent investigation and analysis of an investment in the transactions contemplated in this presentation.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION (“SEC”) NOR ANY STATE OR TERRITORIAL SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESENTATION IS TRUTHFUL OR COMPLETE.
FORWARD-LOOKING STATEMENTS
This presentation may include ‘’forward-looking statements.‘’ To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Autonomix Medicial, Inc.’s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’ ‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’ ‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’
Although Autonomix Medical Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Autonomix are highly speculative. Investing in shares of Autonomix involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.
Autonomix intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Autonomix, the offering and any other related topics, please review the registration statement that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.
USE OF DATA
The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein. Any data on past performance or modeling contained herein is not an indication as to future performance. Autonomix assumes no obligation to update the information in this presentation.
Autonomix is committed to protecting your privacy. This Privacy Policy outlines our practices concerning the collection, use, and protection of your personal information when you visit our website or use our services.
1. Information We Collect
We may collect personal information that you voluntarily provide to us, including but not limited to:
We may also collect non-personal information, such as:
2. How We Use Your Information
We may use your personal information for various purposes, including but not limited to:
3. Cookies and Tracking Technologies
We use cookies and similar tracking technologies to collect information about your browsing behavior on our website. You can manage your cookie preferences through your browser settings.
4. Disclosure of Your Information
We may share your personal information with third parties under the following circumstances:
5. Your Rights
You have the right to:
6. Data Security
We take reasonable measures to protect your personal information from unauthorized access, disclosure, alteration, or destruction. However, no method of data transmission over the internet or electronic storage is entirely secure. Therefore, we cannot guarantee its absolute security.
7. Children’s Privacy
Our website and services are not intended for children under the age of 13. We do not knowingly collect personal information from children. If you believe that a child has provided us with their personal information, please contact us, and we will take appropriate steps to delete the information.
8. Changes to this Privacy Policy
We may update this Privacy Policy from time to time to reflect changes in our practices or for other operational, legal, or regulatory reasons. We encourage you to review this Privacy Policy periodically for any updates.
9. Contact Us
If you have any questions or concerns about this Privacy Policy or our data practices, please contact us at autonomix@jtcir.com.
1. Acceptance of Terms
By accessing and using this website, you agree to abide by these Terms and Conditions, as well as any applicable laws and regulations. If you do not agree with these terms, please refrain from using this website.
2. Use of Content
All content on this website, including but not limited to text, images, graphics, videos, and logos, is the property of Autonomix or its affiliates and is protected by intellectual property laws. You may not reproduce, distribute, or display any content without prior written permission.
3. User Conduct
You agree not to engage in any of the following activities while using this website:
4. Privacy Policy
Your use of this website is also governed by our Privacy Policy, which outlines how we collect, use, and protect your personal information. By using this website, you consent to the practices described in our Privacy Policy.
5. Links to Third-Party Websites
This website may contain links to third-party websites. These links are provided for convenience only, and Autonomix does not endorse or assume responsibility for the content or practices of these websites. Accessing third-party websites is at your own risk.
6. Disclaimer of Warranties
This website is provided “as is,” without any warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose, or non-infringement. Autonomix does not warrant that the website will be error-free or uninterrupted.
7. Limitation of Liability
To the fullest extent permitted by law, Autonomix shall not be liable for any direct, indirect, incidental, consequential, or punitive damages arising out of or related to your use of this website. This includes but is not limited to any loss of data or profits.
8. Governing Law
These Terms and Conditions shall be governed by and construed in accordance with the laws of the United States. Any disputes arising under these terms shall be subject to the exclusive jurisdiction of the courts in the United States.
9. Changes to Terms and Conditions
Autonomix reserves the right to modify or revise these Terms and Conditions at any time. It is your responsibility to review this page periodically for updates. Your continued use of the website after any changes signifies your acceptance of the revised terms.
10. Contact Information
If you have any questions or concerns about these Terms and Conditions, please contact us at autonomix@jtcir.com.